{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T21:18:05Z","timestamp":1764364685675,"version":"3.40.5"},"reference-count":0,"publisher":"Instituto Nacional de Salud (Peru)","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Peru Med Exp Salud Publica"],"abstract":"<jats:p>Objetivos. Analizar el impacto presupuestario de upadacitinib (UPA) 15 mg + metotrexato (MTX) para el tratamiento de la artritis reumatoide (AR) moderada a\u00a0 grave en pacientes con respuesta inadecuada a los f\u00e1rmacos antirreum\u00e1ticos modificadores de la enfermedad convencionales (RI-DMARc) desde la\u00a0 perspectiva de la seguridad social y los sectores de\u00a0 salud privados en Argentina. Materiales y m\u00e9todos. Se\u00a0 desarroll\u00f3 un modelo de an\u00e1lisis de impacto\u00a0 presupuestario para una cohorte hipot\u00e9tica de 100,000\u00a0 adultos con cobertura de seguro de salud que fueron\u00a0 diagnosticados con AR en un horizonte de tiempo de 5\u00a0 a\u00f1os. Los par\u00e1metros del modelo se obtuvieron a trav\u00e9s de una revisi\u00f3n de la literatura y se validaron con expertos locales. Los costos se expresan en d\u00f3lares\u00a0 estadounidenses (USD) para el 2024. Resultados. La\u00a0 introducci\u00f3n de UPA 15 mg + MTX para el tratamiento\u00a0 de AR moderada a grave y RI-DMARc result\u00f3 en un costo incremental m\u00ednimo, con un costo acumulado total a cinco a\u00f1os de USD 1.855 para la seguridad social y USD 1.812 para el sector privado de salud, lo que representa aproximadamente el 2% del presupuesto total. El costo de adquisici\u00f3n de UPA fue la variable m\u00e1s influyente en\u00a0 el an\u00e1lisis de sensibilidad. Conclusiones. La introducci\u00f3n de UPA 15 mg + MTX para el tratamiento de AR genera un incremento de costos marginal para el sistema de salud en Argentina, lo cual es especialmente importante en contextos de presupuestos limitados. Proporcionar estimaciones basadas en la evidencia es una herramienta valiosa para ayudar a tomar decisiones informadas sobre la asignaci\u00f3n eficiente de recursos en salud.<\/jats:p>","DOI":"10.17843\/rpmesp.2024.412.12934","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T19:52:33Z","timestamp":1718999553000},"page":"129-38","source":"Crossref","is-referenced-by-count":2,"title":["Budget impact of upadacitinib in patients with moderate to severe rheumatoid arthritis in Argentina","Impacto presupuestario de upadacitinib en pacientes con artritis reumatoide moderada a severa en Argentina"],"prefix":"10.17843","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5511-3561","authenticated-orcid":false,"given":"Natalia","family":"Esp\u00ednola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9381-3902","authenticated-orcid":false,"given":"Anastasia","family":"Secco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Balan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Kanevsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Calvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Morisset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4437-0073","authenticated-orcid":false,"given":"Ariel","family":"Bardach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2914-5022","authenticated-orcid":false,"given":"Federico","family":"Augustovski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7920","published-online":{"date-parts":[[2024,6,21]]},"container-title":["Revista Peruana de Medicina Experimental y Salud P\u00fablica"],"original-title":[],"link":[{"URL":"https:\/\/rpmesp.ins.gob.pe\/index.php\/rpmesp\/article\/download\/12934\/5626","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/rpmesp.ins.gob.pe\/index.php\/rpmesp\/article\/download\/12934\/5626","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T19:52:47Z","timestamp":1718999567000},"score":1,"resource":{"primary":{"URL":"https:\/\/rpmesp.ins.gob.pe\/index.php\/rpmesp\/article\/view\/12934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":0,"URL":"https:\/\/doi.org\/10.17843\/rpmesp.2024.412.12934","relation":{},"ISSN":["1726-4642","1726-4634"],"issn-type":[{"type":"electronic","value":"1726-4642"},{"type":"print","value":"1726-4634"}],"subject":[],"published":{"date-parts":[[2024,6,21]]}}}